Naobios
Naobios is a GMP-certified company with extensive experience in bioprocess development and contract manufacturing services of virus-based products, including viral vectors, vaccines, oncolytic viruses, and challenge agents. It aims to support the rapid and high-quality development of drug candidates from initial stages to clinical and commercial production, leveraging its technical expertise and state-of-the-art facilities.
Industries
Nr. of Employees
small (1-50)
Naobios
Saint-herblain, Pays de la Loire, France, Europe
Products
Live viral vaccine supply (clinical batches)
Clinical-scale batches of live viral vaccines manufactured under GMP for clinical evaluation.
Inactivated viral vaccine supply (clinical batches)
Clinical-scale manufacture of inactivated viral vaccines using validated inactivation processes and GMP testing.
Oncolytic viruses and ATMP manufacturing
Process development and GMP production for oncolytic viruses and advanced therapy medicinal products intended for clinical evaluation.
Human Viral Challenge Agents (HVCA)
Manufacture and characterization of viral challenge agents to support controlled human infection model studies, produced to a GMP-aligned standard where required.
Exosome manufacturing (development-stage)
Process development activities to extend manufacturing capabilities to extracellular vesicles/exosomes using segregated processes and cleaning controls.
Live viral vaccine supply (clinical batches)
Clinical-scale batches of live viral vaccines manufactured under GMP for clinical evaluation.
Inactivated viral vaccine supply (clinical batches)
Clinical-scale manufacture of inactivated viral vaccines using validated inactivation processes and GMP testing.
Oncolytic viruses and ATMP manufacturing
Process development and GMP production for oncolytic viruses and advanced therapy medicinal products intended for clinical evaluation.
Human Viral Challenge Agents (HVCA)
Manufacture and characterization of viral challenge agents to support controlled human infection model studies, produced to a GMP-aligned standard where required.
Exosome manufacturing (development-stage)
Process development activities to extend manufacturing capabilities to extracellular vesicles/exosomes using segregated processes and cleaning controls.
Services
Development and optimization of upstream and downstream processes for viral vaccines, viral vectors and oncolytic viruses, including microcarrier and adherent-cell strategies.
Manufacture of investigational drug substances and clinical batches under GMP, including campaign-based production, cell/virus banking and clinical lot release testing.
Generation and storage of Master and Working Cell Banks and viral seed stocks for clinical manufacturing campaigns.
Development, qualification and validation of analytical assays required for characterization, QC release and stability assessment of viral products.
Design and execution of stability studies for clinical materials and long-term storage of investigational products.
Manufacture and characterization of viral challenge agents for controlled human infection model studies using GMP-aligned processes and risk analysis.
Development and optimization of upstream and downstream processes for viral vaccines, viral vectors and oncolytic viruses, including microcarrier and adherent-cell strategies.
Manufacture of investigational drug substances and clinical batches under GMP, including campaign-based production, cell/virus banking and clinical lot release testing.
Generation and storage of Master and Working Cell Banks and viral seed stocks for clinical manufacturing campaigns.
Development, qualification and validation of analytical assays required for characterization, QC release and stability assessment of viral products.
Design and execution of stability studies for clinical materials and long-term storage of investigational products.
Manufacture and characterization of viral challenge agents for controlled human infection model studies using GMP-aligned processes and risk analysis.
Expertise Areas
- Bioprocess development (upstream and downstream)
- GMP biomanufacturing for viral products
- Viral vaccine and viral vector production
- Oncolytic virus manufacturing
Key Technologies
- Microcarrier-based cell culture
- Fixed-bed bioreactors
- Single-use stirred-tank bioreactors
- Bench-scale bioreactor systems (0.7–40 L)
News & Updates
Participation of Naobios at the JNBB 2025 to promote innovation and bioproduction development.
Webinar on challenges in virus and vaccine process development, scale-up, and GMP manufacturing, featuring Naobios experts.
Naobios teams will attend CPHI Worldwide to discuss collaborations and showcase capabilities.
Naobios announces the opening of a new BSL3 GMP manufacturing suite for handling Risk Group 3 organisms.
Naobios manufactures FluGen’s M2SR influenza vaccine candidate for clinical trials.
Naobios signs an agreement to evaluate the EB66® cell line for virus production.
Participation of Naobios at the JNBB 2025 to promote innovation and bioproduction development.
Webinar on challenges in virus and vaccine process development, scale-up, and GMP manufacturing, featuring Naobios experts.
Naobios teams will attend CPHI Worldwide to discuss collaborations and showcase capabilities.
Naobios announces the opening of a new BSL3 GMP manufacturing suite for handling Risk Group 3 organisms.
Naobios manufactures FluGen’s M2SR influenza vaccine candidate for clinical trials.
Naobios signs an agreement to evaluate the EB66® cell line for virus production.